<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
<th>Abstract</th>
</tr>
</thead>
<tbody>
<tr>
<td>3117</td>
<td>Highlights from Recent Cancer Literature</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3119</td>
<td>MAX and MYC: A Heritable Breakup</td>
<td>Alberto Caezón and Mercedes Robledo</td>
<td></td>
</tr>
<tr>
<td>3125</td>
<td>Cellular Constituents of Immune Escape within the Tumor Microenvironment</td>
<td>Sid P. Kerkar and Nicholas P. Restifo</td>
<td></td>
</tr>
<tr>
<td>3131</td>
<td>The Continuum Model of Selection in Human Tumors: General Paradigm or Niche Product?</td>
<td>Simon Leedham and Ian Tomlinson</td>
<td></td>
</tr>
<tr>
<td>3135</td>
<td>Stat3 Activation in Urothelial Stem Cells Leads to Direct Progression to Invasive Bladder Cancer</td>
<td>Philip Levy Ho, Erica Julianne Lay, Weiguo Jian, Diana Parra, and Keith Syson Chan</td>
<td></td>
</tr>
<tr>
<td>3143</td>
<td>Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors</td>
<td>Youngshang Pak, Yujian Zhang, Ira Pastan, and Byungkook Lee</td>
<td><strong>Précis:</strong> This study challenges our expectations by presenting a mathematical model suggesting that antigen shedding will enhance rather than inhibit the delivery of recombinant immunotoxins.</td>
</tr>
<tr>
<td>3153</td>
<td>Breast Cancer Cell Uptake of the Inflammatory Mediator Neutrophil Elastase Triggers an Anticancer Adaptive Immune Response</td>
<td>Elizabeth A. Mittendorf, Gheath Alatrash, Na Qiao, Yun Wu, Pariya Sukhumalchandra, Lisa S. St. John, Anne V. Philips, Haile Xiao, Mao Zhang, Kathryn Riisaard, Karen Clise-Dwyer, Sijie Lu, and Jeffrey J. Moidreem</td>
<td><strong>Précis:</strong> Findings reveal an intriguing mechanism through which tumor-associated neutrophils present in the tumor microenvironment can trigger an antigen-specific cytolytic T-cell response against the malignant cells present there.</td>
</tr>
<tr>
<td>3163</td>
<td>Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies</td>
<td>Inge Verbrugge, Jim Hagekyriakou, Leslie L. Sharp, Mara Galli, Alison West, Nicole M. McLaughlin, Hélène Duret, Hideo Yagita, Bicky W. Johnstone, Mark J. Smyth, and Nicole M. Haynes</td>
<td><strong>Précis:</strong> Findings show how systemically delivered monoclonal antibodies that can concomitantly stimulate antitumor immunity and degrade tumoral immunosuppression can act as powerful adjuvants to improve the efficacy of cancer radiotherapy, with immediate translational potential as immunoradiotherapy.</td>
</tr>
<tr>
<td>3175</td>
<td>CXCL10 Promotes Osteolytic Bone Metastasis by Enhancing Cancer Outgrowth and Osteoclastogenesis</td>
<td>Jong-Ho Lee, Ha-Neui Kim, Kyung-Ok Kim, Won Jong Jin, Seungbok Lee, Hong-Hee Kim, Hyunil Ha, and Zang Hee Lee</td>
<td><strong>Précis:</strong> Findings advance understanding of the microenvironmental contributions in the bone that permit the development of osteolytic bone metastasis, with implications for treatment of this common aspect of malignant progression in some common cancers.</td>
</tr>
</tbody>
</table>
MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors
Alexa B. Turke, Youngchul Song, Carlotta Costa, Rebecca Cook, Carlos L. Arteaga, John M. Asara, and Jeffrey A. Engelman

Précis: Findings suggest that, by unleashing ERBB/PI3K/AKT signaling in cancer cells, MEK inhibitors might have complex effects on cancer pathophysiology, with implications for clinical trial design.

DED2 Phosphorylation of Survivin–ΔEx3 Contributes to a DNA Damage–Sensing Checkpoint in Cancer
Alessia Leporegolo, Michele Tavecchio, Sofia Lisanti, Jagadish C. Ghosh, Takehiko Dohi, Alice Faversans, Valentina Vaira, Silvana Bosari, Nobuhiko Tanigawa, Domenico Delia, Andrew V. Kossenkov, Louise C. Showe, and Dario C. Altieri

Précis: This study identifies a novel role of the checkpoint kinase Chk2 in controlling sensing of double-strand DNA breaks in tumor cells.

Oncogenic PI3K Mutations Lead to NF-κB–Dependent Cytokine Expression following Growth Factor Deprivation
Jessica E. Hutti, Adam D. Pfefferle, Sean C. Russell, and Albert S. Baldwin

Précis: This important study furthers a deepening trend in the field by enhancing our understanding of how the most common mutations in cancer not only exert autonomous effects in cancer cells but also powerfully influence the local tumor microenvironment to support the outgrowth of these cells.

TMEM16A Induces MAPK and Contributes Directly to Tumorigenesis and Cancer Progression

Précis: A calcium-activated chloride channel is shown to promote tumorigenesis in head and neck cancers via signaling through the Ras/Raf/MEK pathway and therefore may represent a novel therapeutic target.
PREVENTION AND EPIDEMIOLOGY

3282 Increased Caffeine Intake Is Associated with Reduced Risk of Basal Cell Carcinoma of the Skin
Fengju Song, Abrar A. Qureshi, and Jiali Han
 précis: This prospective analysis shows an inverse association between caffeine intake and the risk of basal cell carcinoma in 2 large national cohorts.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

3290 Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma
Sandro Jube, Zeyana S. Rivera, Marco E. Bianchi, Amy Powers, Ena Wang, Ian Pagano, Harvey I. Pass, Giovanni Gaudino, Michele Carbone, and Haining Yang
 précis: This study offers a preclinical proof-of-principle that therapies aimed at blocking HMGB1-driven inflammation may be beneficial to patients with mesothelioma, especially at early stages of tumor growth.

3302 Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET
Lu Xu, Eiki Kikuchi, Chunxiao Xu, Hiromichi Ebi, Dalia Ercan, Katherine A. Cheng, Robert Padera, Jeffrey A. Engelman, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura, and Kwok-Kin Wong
 précis: Using a bitransgenic murine lung cancer model, this study offers preclinical proof-of-principle that combination therapies targeting EGFR and MET overcome tyrosine kinase inhibitor resistance in non–small cell lung cancer.

3312 Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
Hong Ren, Zhi-Ping Tan, Xin Zhu, Katherine Crosby, Herbert Haack, Jian-Min Ren, Sean Beausoleil, Albrecht Moritz, Gregory Innocenti, John Rush, Yi Zhang, Xin-Min Zhou, Ting-Lei Gu, Yi-Feng Yang, and Michael J. Comb
 précis: Findings suggest the use of ALK kinase inhibitors now in clinical development as potential agents for treatment of some patients with serous ovarian carcinoma or stromal sarcoma.

3324 Antibody Targeting of Cell-Bound MUC1 SEA Domain Kills Tumor Cells
Edward Pichinuk, Itai Benhar, Oded Jacob, Michael Chalik, Lotem Weiss, Ravit Ziv, Carolyn Sympom, Amolikumar Karwa, Nechama I. Smorodinsky, Daniel B. Rubinstein, and Daniel H. Wreschner
 précis: Findings explore the development of a universal class of anticancer antibodies, showing high-affinity binding and potent killing of cancer and cancer stem cells that highly express a common cancer antigen.

3337 Glucose-Regulated Protein 78 Controls Cross-talk between Apoptosis and Autophagy to Determine Antiestrogen Responsiveness
Katherine L. Cook, Ayesha N. Shajahan, Anni Wärri, Lu Jin, Leena A. Hilakivi-Clarke, and Robert Clarke
 précis: Expression of an endoplasmic reticulum-located chaperone protein is shown to play a role in the development of acquired antiestrogen resistance, suggesting that the unfolded protein response may be an adaptation to stress in estrogen receptor–positive breast cancer.

3344 Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency
Wendy L. See, I-Li Tan, Joydeep Mukherjee, Theodore Nicolaides, and Russell O. Pieper
 précis: This study offers immediate implications for stratification of brain cancer patients who might be treated with MEK inhibitors.

3350 The Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth
Zhongguang Luo, Guangyang Yu, Hyun Woo Lee, Lihui Li, Lingyan Wang, Dongjin Yang, Yongfu Pan, Chan Ding, Jing Qian, Lijun Wu, Yiwai Chu, Jing Yi, Xiangdong Wang, Yi Sun, Lak Shin Jeong, Jie Liu, and Lijun Jia
 précis: Findings offer preclinical evidence for therapeutic efficacy of a first-in-class neddylation inhibitor to treat liver cancer and provide a mechanistic rationale for its combination with an autophagy inhibitor.
Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
Dedra H. Fagan, Ryan R. Uselman, Deepali Sachdev, and Douglas Yee

Précis: Findings in a preclinical breast cancer model of tamoxifen resistance may explain the reason for the lack of clinical benefit observed in trials that combine anti-IGF1 receptor and antiestrogen therapies.

TUMOR AND STEM CELL BIOLOGY

Definition of Genetic Events Directing the Development of Distinct Types of Brain Tumors from Postnatal Neural Stem/Progenitor Cells
Falk Hertwig, Katharina Meyer, Sebastian Braun, Sara Ek, Rainer Spang, Cosima V. Pfenninger, Isabella Artner, Gaëlle Prost, Xinhin Chen, Jaclyn A. Biegel, Alexander R. Judkins, Elisabet Englund, and Ulrike A. Nuber

Précis: This study reveals that, within malignant brain tumors derived from a common precursor cell pool, the temporal order of genetic events that accumulate is a critical determinant of the histopathologic phenotype that emerges.

Distinct microRNA Expression Profiles in Prostate Cancer Stem/Progenitor Cells and Tumor-Suppressive Functions of let-7
Can Liu, Kevin Kelinar, Alexander V. Vlassov, David Brown, Junchen Wang, and Dean G. Tang

Précis: microRNA expression profiling performed in prostate cancer stem/progenitor cells identifies a relatively small signature of functionally significant tumor-suppressive genes in the control of prostate cancer stem cell activity.

PTEN and NF1 Inactivation in Schwann Cells Produces a Severe Phenotype in the Peripheral Nervous System That Promotes the Development and Malignant Progression of Peripheral Nerve Sheath Tumors
Vincent W. Keng, Eric P. Rahmann, Adrienne L. Watson, Barbara R. Tschida, Christopher L. Moertel, Walter J. Jessen, Tilat A. Rizvi, Margaret H. Collins, Nancy Ratner, and David A. Largaespada

Précis: This study establishes a mouse model that can rapidly recapitulate the histologies associated with onset of human neurofibromas and their malignant progression to high-grade malignant nerve tumors, based on genetic mutations that are relevant to the human tumor setting.

CD44s Regulates the TGF-β–Mediated Mesenchymal Phenotype and Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
Kosuke Mima, Hirohisa Okabe, Takatsugu Ishimoto, Hiromitsu Hayashi, Shigeki Nakagawa, Hideyuki Kuroki, Masayuki Watanabe, Toru Beppu, Mayumi Tamada, Osamu Nagato, Hideyuki Saya, and Hideo Baba

Précis: The so-called standard isoform of a stem cell marker plays a crucial role in mesenchymal phenotypes associated with progression of hepatocellular carcinoma, with implications for therapeutic targeting of this deadly disease.

FRMD4A Upregulation in Human Squamous Cell Carcinoma Promotes Tumor Growth and Metastasis and Is Associated with Poor Prognosis
Stephen J. Goldie, Klaas W. Mulder, David Wei-Min Tan, Scott K. Lyons, Andrew H. Sims, and Fiona M. Watt

Précis: A candidate stem cell marker implicated in epithelial polarization is found to be a key regulator of metastatic growth in head and neck cancers, with implications for therapeutic targeting of this aggressive and increasingly common disease.
ABOUT THE COVER

Malignant mesothelioma cells secrete the damage-associated molecular pattern protein HMGB1 that promotes tumor progression and sustains the malignant phenotype. HMGB1-secreting mesothelioma cells are addicted to HMGB1, and their anchorage independent growth is impaired by the antagonist BoxA or by a HMGB1 specific monoclonal antibody (mAb), or by a mAb against HMGB1 receptor RAGE, as indicated by the reduced number and size of colonies, compared to controls. For details, see article by Jube et al. on page 3290 of this issue.
## 72 (13)

*Cancer Res* 2012;72:3117-3436.

### Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/72/13

### E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

### Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

### Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.